BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:47 PM
 | 
Aug 27, 2009
 |  BC Extra  |  Company News

ODAC to review GSK's pazopanib

FDA's Oncologic Drugs Advisory Committee will meet on Oct. 5 to discuss an NDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Votrient pazopanib to treat advanced...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >